Contributions
Abstract: PB1688
Type: Publication Only
Background
IRAIN which is produced from the insulin-like growth factor type I receptor (IGF1R) imprinted locus is a newly identified lncRNA. There are very little knowledge about the specific role of this lncRNA in tumorogenesis presses. Recent studies were revealed that IRAIN is down-regulated in leukemia cell lines and viral expression of the IRAIN lncNRA inhibits tumor cell migration, suggesting a tumor suppressor function for this transcript.
Aims
In this study, we attempted to examine the expression level of IRAIN in different cytogenetic subtypes of AML patients.
Methods
Using quantitative polymerase chain reaction (qPCR) the expression level of IRAIN were analyzed in bone marrow specimen of AML patients (n=76) and healthy individuals (n=18).
Results
IRAIN expression was found to be remarkably decreased in AML patients compared with healthy individuals (p= 0.02). Significant IRAIN down-regulation was observed in all FAB types except for the M3 (p= 0.11). When we analyzed the expression level of IRAIN in different cytogenetic subtypes of AML patients the statistically down-regulation of IRAIN was observed only in poor prognosis AML patients (p= 0.008).
Conclusion
Our results suggest that down-regulation of IRAIN lncNRA might play a role in the AML development and hence may be a potential prognostic factor and serve as therapeutic target for AML treatment.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): AML
Abstract: PB1688
Type: Publication Only
Background
IRAIN which is produced from the insulin-like growth factor type I receptor (IGF1R) imprinted locus is a newly identified lncRNA. There are very little knowledge about the specific role of this lncRNA in tumorogenesis presses. Recent studies were revealed that IRAIN is down-regulated in leukemia cell lines and viral expression of the IRAIN lncNRA inhibits tumor cell migration, suggesting a tumor suppressor function for this transcript.
Aims
In this study, we attempted to examine the expression level of IRAIN in different cytogenetic subtypes of AML patients.
Methods
Using quantitative polymerase chain reaction (qPCR) the expression level of IRAIN were analyzed in bone marrow specimen of AML patients (n=76) and healthy individuals (n=18).
Results
IRAIN expression was found to be remarkably decreased in AML patients compared with healthy individuals (p= 0.02). Significant IRAIN down-regulation was observed in all FAB types except for the M3 (p= 0.11). When we analyzed the expression level of IRAIN in different cytogenetic subtypes of AML patients the statistically down-regulation of IRAIN was observed only in poor prognosis AML patients (p= 0.008).
Conclusion
Our results suggest that down-regulation of IRAIN lncNRA might play a role in the AML development and hence may be a potential prognostic factor and serve as therapeutic target for AML treatment.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): AML